Noemi Laprovitera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3706243/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sickle Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report. American Journal of Case Reports, 2022, 23, e934220.	0.3	0
2	The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 113.	3.5	9
3	Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Mechanisms of Ageing and Development, 2021, 193, 111413.	2.2	89
4	Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers, 2021, 13, 451.	1.7	24
5	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. Frontiers in Cell and Developmental Biology, 2021, 9, 666156.	1.8	12
6	MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Molecular Oncology, 2021, 15, 2732-2751.	2.1	14
7	Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease. Cell Death and Disease, 2021, 12, 1150.	2.7	6
8	Abstract 5432: Cancer of unknown primary site-of-origin: An enigma ready to be miR-solved. , 2020, , .		0
9	Abstract 5361: Isolation and genetic characterization of circulating tumor cells from cancer of unknown primary. , 2020, , .		0
10	The Non-Coding RNA Journal Club: Highlights on Recent Papers—7. Non-coding RNA, 2019, 5, 40.	1.3	2
11	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. Epigenomics, 2019, 11, 587-604.	1.0	29
12	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988554.	1.4	25
13	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Letters, 2018, 419, 84-95.	3.2	52
14	Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR. Frontiers in Oncology, 2018, 8, 447.	1.3	15
15	Abstract 3313: Epigenetic biomarkers of prognosis in stage IIA colon cancer. Cancer Research, 2018, 78, 3313-3313.	0.4	1